Study on the Use of Sarilumab in Patients With COVID-19 Infection
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04386239 |
Recruitment Status : Unknown
Verified January 2021 by Stefano Rusconi, ASST Fatebenefratelli Sacco.
Recruitment status was: Recruiting
First Posted : May 13, 2020
Last Update Posted : July 20, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID19 | Drug: Sarilumab Prefilled Syringe | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Monocentric, escalation dose |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Pilot Study on the Use of Sarilumab in Patients With COVID-19 Infection |
Actual Study Start Date : | January 1, 2021 |
Estimated Primary Completion Date : | December 2021 |
Estimated Study Completion Date : | December 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Covid-19
Patients with documented (chest X-Ray or Computed Tomography scan) Covid-19 (Polymerase Chain Reaction+ swab test) interstitial pneumonia and BCRSS ≥3 and <4 will be requested consent to the study.
|
Drug: Sarilumab Prefilled Syringe
Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
Other Name: Sarilumab |
- Proportion of patients who show an improvement of the respiratory function [ Time Frame: 6 weeks ]Clinical efficacy of sarilumab in adult patients hospitalized due to severe Covid-19 pneumonia based on the proportion of patients who show an improvement of the respiratory function, described as ≥30% decrease in oxygen requirement compared to baseline (as defined as the ratio of O2 flow through the Venturi mask).
- Evaluation of the time to resolution of fever [ Time Frame: 6 weeks ]Evaluation of the time to resolution of fever, defined as body temperature ≤36.6°C axilla, ≤37.8°C rectal or tympanic for at least 48 hours without antipyretics in patients with fever at baseline.
- Evaluation of the viral load on blood and sputum for COVID-19 [ Time Frame: Before administration of sarilumab, 48 hours and 96 hours after administration ]Evaluation of the viral load on blood and sputum for COVID-19
- Evaluation of the plasma concentration of GM-CSF [ Time Frame: Pre-treatment and 96 and 120 hours post-treatment ]Evaluation of the plasma concentration of GM-CSF
- Evaluation of the plasma concentration of Il-6 [ Time Frame: Pre-treatment and 96 and 120 hours post-treatment ]Evaluation of the plasma concentration of Il-6
- Evaluation of the plasma concentration of TNF-α [ Time Frame: Pre-treatment and 96 and 120 hours post-treatment ]Evaluation of the plasma concentration of TNF-α
- Evaluation of the rate of progression of White Blood Cell (WBC) fraction [ Time Frame: 96 and 120 hours post-treatment ]Evaluation of the rate of progression of WBC fraction of immature granulocytes - IG - (absolute count).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 84 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years and < 85 years.
- Documented (chest X-Ray or TC scan), severe (BCRSS ≥3 and <4) interstitial pneumonia with respiratory failure (requiring supplemental oxygen) with positive Covid-19 swab testing.
- Worsening of respiratory exchanges such as to require ventilation with Venturi mask >31% (6L/minute).
- Increased levels of D-dimer (> 1500 ng/mL) or D-dimer progressively increasing (over 3 consecutive measurements) and reaching ≥ 1000 ng/mL.
- Signed informed consent.
Exclusion Criteria:
- Age < 18 years or ≥ 85 years.
- AST / ALT > 5x Upper normal limit.
- Neutrophil count lower than 500 cells / mL.
- Platelet count lower than 50,000 cells / mL.
- Documented sepsis due to infections other than Covid-19.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04386239
Contact: Agostino Riva, MD | 02-39042676 | agostino.riva@unimi.it | |
Contact: Massimo Galli, Professor | massimo.galli@unimi.it |
Italy | |
Divisione Clinicizzata di Malattie Infettive, ASST FBF-Sacco | Recruiting |
Milano, MI, Italy, 20157 | |
Contact: Agostino Riva, M.D. 00390239042676 agostino.riva@unimi.it |
Principal Investigator: | Massimo Galli, Professor | University of Milan |
Documents provided by Stefano Rusconi, ASST Fatebenefratelli Sacco:
Responsible Party: | Stefano Rusconi, Co-investigator, ASST Fatebenefratelli Sacco |
ClinicalTrials.gov Identifier: | NCT04386239 |
Other Study ID Numbers: |
COVID-SARI-001 |
First Posted: | May 13, 2020 Key Record Dates |
Last Update Posted: | July 20, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Coronavirus Pandemic Lombardy |
COVID-19 Infections Respiratory Tract Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |